RR

Rob Readnour

Director at AN2 Therapeutics

Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies; Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets; Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health; Applied LifeSciences & Systems Poultry, a poultry vaccine delivery device company developing a high-throughput vaccine delivery system to individually vaccinate post-hatch chicks; and Convetra, a company developing a radiosynoviorthesis product to treat chronic osteoarthritis in dogs.

Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years, where he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health, and he developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.

Prior to Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


AN2 Therapeutics

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases.


Industries

Employees

11-50

Links